Cost–effectiveness of overactive bladder treatments from a US commercial and payer perspective

The cost–effectiveness of treatment options (anticholinergics, β3-adrenoceptor agonists, onabotulinumtoxinA, sacral nerve stimulation and percutaneous tibial stimulation [the latter two including new rechargeable neurostimulators]) for the management of overactive bladder (OAB) were compared with be...

Full description

Saved in:
Bibliographic Details
Published in:Journal of comparative effectiveness research 2023-02, Vol.12 (2), p.e220089-e220089
Main Authors: Murray, Brian, Miles-Thomas, Jennifer, Park, Amy J, Nguyen, Victor B, Tung, Amy, Gillard, Patrick, Lalla, Anjana, Nitti, Victor W, Chermansky, Christopher J
Format: Article
Language:English
Subjects:
Aged
anticholinergic
Botulinum Toxins, Type A - therapeutic use
Cholinergic Antagonists
Cost-Benefit Analysis
cost–effectiveness
Humans
Markov model
Medicare
onabotulinumtoxinA
overactive bladder
Quality-Adjusted Life Years
quality-adjusted life-year
rechargeable sacral nerve stimulation
United States
Urinary Bladder, Overactive - drug therapy
β3-adrenoceptor agonist
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c460t-2d2918e8aa1ac63191da695b48d1766711a23d7941df3524d452e7f0a533b1bd3
container_end_page e220089
container_issue 2
container_start_page e220089
container_title Journal of comparative effectiveness research
container_volume 12
creator Murray, Brian
Miles-Thomas, Jennifer
Park, Amy J
Nguyen, Victor B
Tung, Amy
Gillard, Patrick
Lalla, Anjana
Nitti, Victor W
Chermansky, Christopher J
description The cost–effectiveness of treatment options (anticholinergics, β3-adrenoceptor agonists, onabotulinumtoxinA, sacral nerve stimulation and percutaneous tibial stimulation [the latter two including new rechargeable neurostimulators]) for the management of overactive bladder (OAB) were compared with best supportive care (BSC) using a previously published Markov model. Cost–effectiveness was evaluated over a 15-year time horizon, and sensitivity analyses were performed using 2- and 5-year horizons. Discontinuation rates, resource utilization, and costs were derived from published sources. Using Medicare and commercial costs over a 15-year time period, onabotulinumtoxinA 100U had incremental cost–effectiveness ratios (ICERs) gained of $39,591/quality-adjusted life-year (QALY) and $42,255/QALY, respectively, versus BSC, which were the lowest ICERs of all assessed treatments. The sensitivity analyses at 2- and 5-year horizons also showed onabotulinumtoxinA to be the most cost-effective of all assessed treatments versus BSC. OnabotulinumtoxinA 100U is currently the most cost-effective treatment for OAB.
doi_str_mv 10.2217/cer-2022-0089
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_31dbbad2d057467385654cb7d75607fb</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_31dbbad2d057467385654cb7d75607fb</doaj_id><sourcerecordid>2767171515</sourcerecordid><originalsourceid>FETCH-LOGICAL-c460t-2d2918e8aa1ac63191da695b48d1766711a23d7941df3524d452e7f0a533b1bd3</originalsourceid><addsrcrecordid>eNp1kUtu1TAUhiMEolXpkCnKkEnAj9hORghd8ahUiQF0bJ3Yx8VVEgfbuVJn7IENsBaWwkrwbcoVHeCJX58_-_ivqueUvGKMqtcGY8MIYw0hXf-oOmWkZY3klD8-jok4qc5TuiGlya7tBXtanXAphVCtOK1gF1L-_f0HOocm-z3OmFIdXB32GOFupR5GsBZjnSNCnnDOqXYxTDXUV59rE6YJo_Ew1jDbXz8XuC3ogjEtm_BZ9cTBmPD8vj-rrt6_-7L72Fx--nCxe3vZmFaS3DDLetphB0DBlBJ6akH2Ymg7S5WUilJg3Kq-pdZxwVrbCobKERCcD3Sw_Ky62Lw2wI1eop8g3uoAXt8thHitIWZvRtSc2mEAyywpnyAV74QUrRmUVUIS5YbierO5lnWY0JpSc4TxgfThzuy_6uuw15SwruuFKIaX94YYvq2Ysp58MjiOMGNYk2aqlKSooAe02VATQ0oR3fEeSvQhZl1i1oeY9SHmwr_493FH-m-oBeg3wK15jZiMx9mg3mblhDd-xv_I_wDSt7l9</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2767171515</pqid></control><display><type>article</type><title>Cost–effectiveness of overactive bladder treatments from a US commercial and payer perspective</title><source>PubMed Central</source><creator>Murray, Brian ; Miles-Thomas, Jennifer ; Park, Amy J ; Nguyen, Victor B ; Tung, Amy ; Gillard, Patrick ; Lalla, Anjana ; Nitti, Victor W ; Chermansky, Christopher J</creator><creatorcontrib>Murray, Brian ; Miles-Thomas, Jennifer ; Park, Amy J ; Nguyen, Victor B ; Tung, Amy ; Gillard, Patrick ; Lalla, Anjana ; Nitti, Victor W ; Chermansky, Christopher J</creatorcontrib><description>The cost–effectiveness of treatment options (anticholinergics, β3-adrenoceptor agonists, onabotulinumtoxinA, sacral nerve stimulation and percutaneous tibial stimulation [the latter two including new rechargeable neurostimulators]) for the management of overactive bladder (OAB) were compared with best supportive care (BSC) using a previously published Markov model. Cost–effectiveness was evaluated over a 15-year time horizon, and sensitivity analyses were performed using 2- and 5-year horizons. Discontinuation rates, resource utilization, and costs were derived from published sources. Using Medicare and commercial costs over a 15-year time period, onabotulinumtoxinA 100U had incremental cost–effectiveness ratios (ICERs) gained of $39,591/quality-adjusted life-year (QALY) and $42,255/QALY, respectively, versus BSC, which were the lowest ICERs of all assessed treatments. The sensitivity analyses at 2- and 5-year horizons also showed onabotulinumtoxinA to be the most cost-effective of all assessed treatments versus BSC. OnabotulinumtoxinA 100U is currently the most cost-effective treatment for OAB.</description><identifier>ISSN: 2042-6305</identifier><identifier>EISSN: 2042-6313</identifier><identifier>DOI: 10.2217/cer-2022-0089</identifier><identifier>PMID: 36655745</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Aged ; anticholinergic ; Botulinum Toxins, Type A - therapeutic use ; Cholinergic Antagonists ; Cost-Benefit Analysis ; cost–effectiveness ; Humans ; Markov model ; Medicare ; onabotulinumtoxinA ; overactive bladder ; Quality-Adjusted Life Years ; quality-adjusted life-year ; rechargeable sacral nerve stimulation ; United States ; Urinary Bladder, Overactive - drug therapy ; β3-adrenoceptor agonist</subject><ispartof>Journal of comparative effectiveness research, 2023-02, Vol.12 (2), p.e220089-e220089</ispartof><rights>2023 AbbVie, Inc.</rights><rights>2023 AbbVie, Inc. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c460t-2d2918e8aa1ac63191da695b48d1766711a23d7941df3524d452e7f0a533b1bd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288955/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288955/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36655745$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Murray, Brian</creatorcontrib><creatorcontrib>Miles-Thomas, Jennifer</creatorcontrib><creatorcontrib>Park, Amy J</creatorcontrib><creatorcontrib>Nguyen, Victor B</creatorcontrib><creatorcontrib>Tung, Amy</creatorcontrib><creatorcontrib>Gillard, Patrick</creatorcontrib><creatorcontrib>Lalla, Anjana</creatorcontrib><creatorcontrib>Nitti, Victor W</creatorcontrib><creatorcontrib>Chermansky, Christopher J</creatorcontrib><title>Cost–effectiveness of overactive bladder treatments from a US commercial and payer perspective</title><title>Journal of comparative effectiveness research</title><addtitle>J Comp Eff Res</addtitle><description>The cost–effectiveness of treatment options (anticholinergics, β3-adrenoceptor agonists, onabotulinumtoxinA, sacral nerve stimulation and percutaneous tibial stimulation [the latter two including new rechargeable neurostimulators]) for the management of overactive bladder (OAB) were compared with best supportive care (BSC) using a previously published Markov model. Cost–effectiveness was evaluated over a 15-year time horizon, and sensitivity analyses were performed using 2- and 5-year horizons. Discontinuation rates, resource utilization, and costs were derived from published sources. Using Medicare and commercial costs over a 15-year time period, onabotulinumtoxinA 100U had incremental cost–effectiveness ratios (ICERs) gained of $39,591/quality-adjusted life-year (QALY) and $42,255/QALY, respectively, versus BSC, which were the lowest ICERs of all assessed treatments. The sensitivity analyses at 2- and 5-year horizons also showed onabotulinumtoxinA to be the most cost-effective of all assessed treatments versus BSC. OnabotulinumtoxinA 100U is currently the most cost-effective treatment for OAB.</description><subject>Aged</subject><subject>anticholinergic</subject><subject>Botulinum Toxins, Type A - therapeutic use</subject><subject>Cholinergic Antagonists</subject><subject>Cost-Benefit Analysis</subject><subject>cost–effectiveness</subject><subject>Humans</subject><subject>Markov model</subject><subject>Medicare</subject><subject>onabotulinumtoxinA</subject><subject>overactive bladder</subject><subject>Quality-Adjusted Life Years</subject><subject>quality-adjusted life-year</subject><subject>rechargeable sacral nerve stimulation</subject><subject>United States</subject><subject>Urinary Bladder, Overactive - drug therapy</subject><subject>β3-adrenoceptor agonist</subject><issn>2042-6305</issn><issn>2042-6313</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNp1kUtu1TAUhiMEolXpkCnKkEnAj9hORghd8ahUiQF0bJ3Yx8VVEgfbuVJn7IENsBaWwkrwbcoVHeCJX58_-_ivqueUvGKMqtcGY8MIYw0hXf-oOmWkZY3klD8-jok4qc5TuiGlya7tBXtanXAphVCtOK1gF1L-_f0HOocm-z3OmFIdXB32GOFupR5GsBZjnSNCnnDOqXYxTDXUV59rE6YJo_Ew1jDbXz8XuC3ogjEtm_BZ9cTBmPD8vj-rrt6_-7L72Fx--nCxe3vZmFaS3DDLetphB0DBlBJ6akH2Ymg7S5WUilJg3Kq-pdZxwVrbCobKERCcD3Sw_Ky62Lw2wI1eop8g3uoAXt8thHitIWZvRtSc2mEAyywpnyAV74QUrRmUVUIS5YbierO5lnWY0JpSc4TxgfThzuy_6uuw15SwruuFKIaX94YYvq2Ysp58MjiOMGNYk2aqlKSooAe02VATQ0oR3fEeSvQhZl1i1oeY9SHmwr_493FH-m-oBeg3wK15jZiMx9mg3mblhDd-xv_I_wDSt7l9</recordid><startdate>20230201</startdate><enddate>20230201</enddate><creator>Murray, Brian</creator><creator>Miles-Thomas, Jennifer</creator><creator>Park, Amy J</creator><creator>Nguyen, Victor B</creator><creator>Tung, Amy</creator><creator>Gillard, Patrick</creator><creator>Lalla, Anjana</creator><creator>Nitti, Victor W</creator><creator>Chermansky, Christopher J</creator><general>Future Medicine Ltd</general><general>Becaris Publishing Ltd</general><general>Becaris Publishing Limited</general><scope>FUMOA</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20230201</creationdate><title>Cost–effectiveness of overactive bladder treatments from a US commercial and payer perspective</title><author>Murray, Brian ; Miles-Thomas, Jennifer ; Park, Amy J ; Nguyen, Victor B ; Tung, Amy ; Gillard, Patrick ; Lalla, Anjana ; Nitti, Victor W ; Chermansky, Christopher J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c460t-2d2918e8aa1ac63191da695b48d1766711a23d7941df3524d452e7f0a533b1bd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Aged</topic><topic>anticholinergic</topic><topic>Botulinum Toxins, Type A - therapeutic use</topic><topic>Cholinergic Antagonists</topic><topic>Cost-Benefit Analysis</topic><topic>cost–effectiveness</topic><topic>Humans</topic><topic>Markov model</topic><topic>Medicare</topic><topic>onabotulinumtoxinA</topic><topic>overactive bladder</topic><topic>Quality-Adjusted Life Years</topic><topic>quality-adjusted life-year</topic><topic>rechargeable sacral nerve stimulation</topic><topic>United States</topic><topic>Urinary Bladder, Overactive - drug therapy</topic><topic>β3-adrenoceptor agonist</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Murray, Brian</creatorcontrib><creatorcontrib>Miles-Thomas, Jennifer</creatorcontrib><creatorcontrib>Park, Amy J</creatorcontrib><creatorcontrib>Nguyen, Victor B</creatorcontrib><creatorcontrib>Tung, Amy</creatorcontrib><creatorcontrib>Gillard, Patrick</creatorcontrib><creatorcontrib>Lalla, Anjana</creatorcontrib><creatorcontrib>Nitti, Victor W</creatorcontrib><creatorcontrib>Chermansky, Christopher J</creatorcontrib><collection>Future Medicine (Open Access)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Journal of comparative effectiveness research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Murray, Brian</au><au>Miles-Thomas, Jennifer</au><au>Park, Amy J</au><au>Nguyen, Victor B</au><au>Tung, Amy</au><au>Gillard, Patrick</au><au>Lalla, Anjana</au><au>Nitti, Victor W</au><au>Chermansky, Christopher J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cost–effectiveness of overactive bladder treatments from a US commercial and payer perspective</atitle><jtitle>Journal of comparative effectiveness research</jtitle><addtitle>J Comp Eff Res</addtitle><date>2023-02-01</date><risdate>2023</risdate><volume>12</volume><issue>2</issue><spage>e220089</spage><epage>e220089</epage><pages>e220089-e220089</pages><issn>2042-6305</issn><eissn>2042-6313</eissn><abstract>The cost–effectiveness of treatment options (anticholinergics, β3-adrenoceptor agonists, onabotulinumtoxinA, sacral nerve stimulation and percutaneous tibial stimulation [the latter two including new rechargeable neurostimulators]) for the management of overactive bladder (OAB) were compared with best supportive care (BSC) using a previously published Markov model. Cost–effectiveness was evaluated over a 15-year time horizon, and sensitivity analyses were performed using 2- and 5-year horizons. Discontinuation rates, resource utilization, and costs were derived from published sources. Using Medicare and commercial costs over a 15-year time period, onabotulinumtoxinA 100U had incremental cost–effectiveness ratios (ICERs) gained of $39,591/quality-adjusted life-year (QALY) and $42,255/QALY, respectively, versus BSC, which were the lowest ICERs of all assessed treatments. The sensitivity analyses at 2- and 5-year horizons also showed onabotulinumtoxinA to be the most cost-effective of all assessed treatments versus BSC. OnabotulinumtoxinA 100U is currently the most cost-effective treatment for OAB.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>36655745</pmid><doi>10.2217/cer-2022-0089</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2042-6305
ispartof Journal of comparative effectiveness research, 2023-02, Vol.12 (2), p.e220089-e220089
issn 2042-6305
2042-6313
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_31dbbad2d057467385654cb7d75607fb
source PubMed Central
subjects Aged
anticholinergic
Botulinum Toxins, Type A - therapeutic use
Cholinergic Antagonists
Cost-Benefit Analysis
cost–effectiveness
Humans
Markov model
Medicare
onabotulinumtoxinA
overactive bladder
Quality-Adjusted Life Years
quality-adjusted life-year
rechargeable sacral nerve stimulation
United States
Urinary Bladder, Overactive - drug therapy
β3-adrenoceptor agonist
title Cost–effectiveness of overactive bladder treatments from a US commercial and payer perspective
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T21%3A21%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cost%E2%80%93effectiveness%20of%20overactive%20bladder%20treatments%20from%20a%20US%20commercial%20and%C2%A0payer%20perspective&rft.jtitle=Journal%20of%20comparative%20effectiveness%20research&rft.au=Murray,%20Brian&rft.date=2023-02-01&rft.volume=12&rft.issue=2&rft.spage=e220089&rft.epage=e220089&rft.pages=e220089-e220089&rft.issn=2042-6305&rft.eissn=2042-6313&rft_id=info:doi/10.2217/cer-2022-0089&rft_dat=%3Cproquest_doaj_%3E2767171515%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c460t-2d2918e8aa1ac63191da695b48d1766711a23d7941df3524d452e7f0a533b1bd3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2767171515&rft_id=info:pmid/36655745&rfr_iscdi=true